ADS Biotec has been named the recipient of the 2025 Governor’s Bioscience Award. Governor Jim Pillen presented the award during Bio Nebraska’s Annual Event on October 2 in Omaha. The award recognizes companies and individuals making outstanding contributions to Nebraska’s thriving bioscience industry.
Governor Pillen emphasized the importance of supporting Nebraska’s bioscience sector. “Supporting Nebraska’s bioscience industry is key to our future,” he said. “It drives innovation, creates high-quality jobs, and strengthens our economy. Companies like ADS Biotec exemplify how we’re building world-class, cutting-edge industries right here at home. I am proud to honor their contributions during Bioscience Month.”
Headquartered in Omaha, ADS Biotec is a global leader in the development, manufacture, and sale of automated instruments and bio-consumables. The company specializes in products used in diagnostic analysis, particularly in cytogenetics, pathology, and molecular genetic testing. Its innovative solutions help laboratories perform complex diagnostic procedures more efficiently and accurately.
ADS Biotec has established a significant international presence. It operates development, sales, and support offices across three continents. Its products are used by laboratories and hospitals in more than 30 countries worldwide. The company’s team, with over 20 years of industry experience, is recognized globally for advanced instrumentation, excellent customer service, and scientific application support.
Vijay Dube, CEO of ADS Biotec, expressed gratitude for the award. “We are deeply honored to receive the 2025 Governor’s Bioscience Award. Our dedicated team has helped grow the company into a global leader in cytogenetic automation systems relied upon by hospitals and diagnostic labs worldwide.”
Dube highlighted the company’s roots in Omaha. “Founded in Omaha over twenty years ago, ADS Biotec has grown significantly. Our Omaha manufacturing facility produces reagents, mRNA purification columns, and buffers for next-generation drugs and vaccines. We’re committed to investing further in Nebraska’s bioscience community, developing new products and processes to support innovation and growth.”
